| Metric | Grade | Score | Evidence & Notes | Horizon |
|---|---|---|---|---|
| FINAL ESEN MASTER SCORE | C+ | 52 | Early-stage biotech with speculative risk profile; positive momentum offset by fundamental challenges and profitability gap. | 6–12M |
| SA Quality/Value Composite | D+ | 38 | Negative EPS (–$5.14), no dividend, no earnings coverage (P/E null). Market cap $5.95B; valuation flags: none triggered, but fundamentals weak. | TTM |
| Zacks Earnings Momentum | C | 55 | Revenue YoY: –46.97% (contraction signal); EPS YoY: null (no comparable). Recent price momentum strong (+9.35% today; 52W return +58.39%). | 1–3M |
| Institutional & Smart Money Flow | B– | 68 | Beta 1.43 (elevated volatility attracts momentum traders). Price +9.35% on day; 52W high $2.95 vs. current $1.17 signals potential accumulation or capitulation phases. Volume data unavailable; assessment constrained. | 1–3M |
| Growth Sustainability & Moat | D | 35 | Revenue declining –46.97% YoY; biotech sector with regulatory exposure (AquaBounty's GM salmon product); no disclosed forward guidance. Moat visibility limited. | 6–12M |
| Valuation & Safety (Pre-Penalty) | C | 50 | P/E null (unprofitable). Enterprise value $5.95B; 52W range $0.70–$2.95 shows extreme volatility. Current price $1.17 is mid-range; no clear margin of safety given earnings losses. | 6–12M |
| Penalty Overlay | –12 pts | –12 | Negative EPS, revenue contraction, high beta, no dividend; profitability risk and liquidity concentration in volatile micro-cap biotech. | 6–12M |
| CONFIDENCE SCORE | C | 61 | Data coverage: metrics available (quote, profile, beta, revenue YoY); earnings date and forward guidance missing. Assessment constrained by limited forward visibility and speculative profile. | 6–12M |
| Volatility & Drawdown Risk | D+ | 40 | Beta 1.43; 52W drawdown from $2.95 to $0.70 = –76%. Current price $1.17. High tail risk in biotech micro-cap; suitable only for risk-tolerant portfolios. | 6–12M |
| Crowding Risk Flag | ELEVATED | 64 | Small-cap biotech attracting retail and momentum traders (evident from +9.35% daily swing, 58% YTD return). Susceptible to sentiment reversals and funding/regulatory news. | 1–3M |
AquaBounty Technologies (AQB) operates in the Biotechnology sector, specifically in genetically modified aquaculture. The company competes in a niche but growing segment (alternative protein/sustainable food) that includes players like Upside Foods, Memphis Meats, and conventional aquaculture producers facing regulatory headwinds and cost pressures.
Relative Positioning: AQB's 52-week return (+58.39%) outpaces broad biotech indices but reflects high volatility characteristic of micro-cap innovation plays. The –46.97% revenue contraction and negative EPS suggest material operational challenges—likely tied to regulatory delays, production constraints, or market adoption barriers for GM salmon products. Comparably-sized biotech peers trading profitably command higher multiples; AQB's unprofitability places it in a higher-risk cohort.
AMBER — ELEVATED CROWDING RISK
The +9.35% intraday move and 58% YTD return indicate active retail/momentum participation. Beta 1.43 suggests amplified swings in response to biotech news flow (FDA updates, regulatory decisions, earnings surprises). Key catalysts: Any adverse regulatory news on GM salmon commercialization or missed production milestones could trigger sharp reversals. Conversely, approval announcements or partnering deals could drive 20%+ rallies. Suitable for: Active traders with tight stop-losses; unsuitable for buy-and-hold value investors.
RED — PROFITABILITY & SUSTAINABILITY IN QUESTION
The –46.97% revenue contraction and –$5.14 EPS signal a company in distress mode or strategic repositioning. Over the next 6–12 months, AQB must demonstrate: (1) revenue stabilization and return to growth; (2) a clear path to GAAP profitability (or gross margin expansion); (3) regulatory approval wins and commercial traction for core products. Without these milestones, the stock risks further downside toward the 52-week low of $0.70. Bull case: Successful FDA approval and ramped production could drive 50%+ upside; however, this requires execution risk premium. Bear case: Continued revenue decline and cash burn pressure could trigger dilutive capital raises or strategic restructuring.
AQB Stock Analysis & Forecast
Is AQB a Good Investment in 2026?
Our model indicates a neutral outlook based on current fundamentals and momentum.
AQB Stock Forecast
Based on recent earnings trends, valuation metrics, and sector performance, AQB shows balanced risk-reward characteristics.
Should You Buy AQB Now?
Investors should consider market conditions, volatility, and long-term positioning before taking a position in AQB.